{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:59:21Z","timestamp":1785416361497,"version":"3.56.0"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cerebrospinal fluid (CSF) penetration of delafloxacin was evaluated in a murine model. Mice received a single 40 mg\/kg intraperitoneal dose. Plasma and CSF samples were collected at five time points over 4 h and analyzed by ultra high-performance liquid chromatography\/tandem mass spectrometry (UPLC-MS\/MS). Pharmacokinetic parameters, including CSF penetration ratio (AUC\n                      <jats:sub>0\u20134h<\/jats:sub>\n                      CSF\/AUC\n                      <jats:sub>0\u20134h<\/jats:sub>\n                      plasma), were determined using a non-compartmental model. The CSF penetration ratio of delafloxacin was 49%. Cmax\/MIC ratios met pharmacokinetic\/pharmacodynamic targets for\n                      <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Streptococcus<\/jats:italic>\n                      spp., but not Enterobacterales.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01660-25","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:00:23Z","timestamp":1768399223000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of cerebrospinal fluid penetration of delafloxacin in a murine model"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-7336","authenticated-orcid":true,"given":"Marin","family":"Lahouati","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x581406","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pital Pellegrin, Service de pharmacie clinique, CHU de Bordeaux","place":["Bordeaux, France"]},{"id":[{"id":"https:\/\/ror.org\/019v7sr25","id-type":"ROR","asserted-by":"publisher"}],"name":"INSERM, BMC, U1034, Univ. Bordeaux","place":["Pessac, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Dias Meireles","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x581406","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pital Pellegrin, Service de pharmacie clinique, CHU de Bordeaux","place":["Bordeaux, France"]},{"id":[{"id":"https:\/\/ror.org\/019v7sr25","id-type":"ROR","asserted-by":"publisher"}],"name":"INSERM, BMC, U1034, Univ. Bordeaux","place":["Pessac, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Rougnon-Glasson","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmaco-Toxicologie Biologique et M\u00e9dico-L\u00e9gale, CH Tarbes-Lourdes","place":["Tarbes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Petitcollin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x581406","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pital Pellegrin, Service de pharmacie clinique, CHU de Bordeaux","place":["Bordeaux, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Xuereb","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x581406","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00f4pital Pellegrin, Service de pharmacie clinique, CHU de Bordeaux","place":["Bordeaux, France"]},{"id":[{"id":"https:\/\/ror.org\/019v7sr25","id-type":"ROR","asserted-by":"publisher"}],"name":"INSERM, BMC, U1034, Univ. Bordeaux","place":["Pessac, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"European Medicines Agency. 2019. Quofenix (delafloxacin). The Netherlands European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/homepage."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00007-10"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3104-3108.2003"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963940"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn110"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/605576"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00647-16"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"},{"key":"e_1_3_2_10_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2024. Breakpoint tables EUCAST v14.0"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0520-8"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00757-x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70100"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01660-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01660-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:01:51Z","timestamp":1770213711000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01660-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"alternative-id":["10.1128\/aac.01660-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01660-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"2025-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01660-25"}}